PMID- 19209252
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20111110
LR  - 20211020
IS  - 1176-6336 (Print)
IS  - 1178-203X (Electronic)
IS  - 1176-6336 (Linking)
VI  - 4
IP  - 4
DP  - 2008 Aug
TI  - Double-blind, randomized trial comparing efficacy and safety of continuing 
      olanzapine versus switching to quetiapine in overweight or obese patients with 
      schizophrenia or schizoaffective disorder.
PG  - 713-20
AB  - We examined the potential risks and benefits of switching from olanzapine to 
      quetiapine in mentally stable, obese, or overweight patients with schizophrenia 
      or schizoaffective disorder. Patients receiving olanzapine were randomized to 
      continuing olanzapine treatment (N =68; 7.5-20 mg/day) or switching to quetiapine 
      (N =65; 300-800 mg/day). Time to relapse was the primary study objective; 
      secondary objectives included changes in weight, metabolic parameters, and 
      psychiatric symptoms, and discontinuation rates. No significant difference in 
      time to relapse was observed (p =0.293), but significantly more patients remained 
      on treatment in the olanzapine group compared with the quetiapine group (70.6% vs 
      43.1%; p =0.002). Olanzapine-treated patients had significantly lower rates of 
      study discontinuation for lack of efficacy and psychiatric adverse events (AEs) 
      compared to quetiapine (2.94% vs 15.38%, p =0.015). Significantly more patients 
      in the olanzapine group experienced an increase in BMI >/=1 kg/m(2). 
      Olanzapine-treated patients experienced significantly greater increases in weight 
      from Weeks 2 through 13. Switching patients with stable disease from olanzapine 
      to quetiapine did not significantly shorten time to relapse, but produced more 
      frequent study discontinuations due to lack of efficacy or psychiatric AEs with 
      moderate but variable improvement in weight and no significant between-group 
      differences in mean changes in metabolic laboratory parameters.
FAU - Deberdt, Walter
AU  - Deberdt W
AD  - Eli Lilly Benelux, Eli Lilly and Company, Brussels, Belgium. 
      deberdt_walter@lilly.com
FAU - Lipkovich, Ilya
AU  - Lipkovich I
FAU - Heinloth, Alexandra N
AU  - Heinloth AN
FAU - Liu, Lin
AU  - Liu L
FAU - Kollack-Walker, Sara
AU  - Kollack-Walker S
FAU - Edwards, Sara E
AU  - Edwards SE
FAU - Hoffmann, Vicki Poole
AU  - Hoffmann VP
FAU - Hardy, Thomas A
AU  - Hardy TA
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Ther Clin Risk Manag
JT  - Therapeutics and clinical risk management
JID - 101253281
PMC - PMC2621385
OTO - NOTNLM
OT  - BMI
OT  - antipsychotic switching
OT  - discontinuation
OT  - relapse
OT  - weight
EDAT- 2009/02/12 09:00
MHDA- 2009/02/12 09:01
PMCR- 2008/12/01
CRDT- 2009/02/12 09:00
PHST- 2009/02/12 09:00 [entrez]
PHST- 2009/02/12 09:00 [pubmed]
PHST- 2009/02/12 09:01 [medline]
PHST- 2008/12/01 00:00 [pmc-release]
AID - tcrm-4-713 [pii]
AID - 10.2147/tcrm.s3153 [doi]
PST - ppublish
SO  - Ther Clin Risk Manag. 2008 Aug;4(4):713-20. doi: 10.2147/tcrm.s3153.